Grants paid by International Myeloma Foundation
EIN 95-4296919 · Studio City, CA · Form 990, Schedule I · NTEE Z99Z
International Myeloma Foundation of Studio City, CA (EIN 95-4296919) reported 26 grants paid totaling $859,999 to 12 recipients in tax years 2018–2025, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$859,999
26 grants
Recipients
12
distinct organizations
Tax years
2018–2025
8 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 3 | $130,000 | — |
| 2019 | 2 | $113,333 | — |
| 2020 | 4 | $130,000 | — |
| 2021 | 3 | $76,666 | — |
| 2022 | 2 | $50,000 | — |
| 2023 | 4 | $120,000 | — |
| 2024 | 5 | $163,333 | — |
| 2025 | 3 | $76,667 | — |
Top recipients
The 12 recipients receiving the most from International Myeloma Foundation, by grants paid, out of 12 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Dana Farber Cancer Institute 04-2263040 | A | Boston, MA | 7 | $246,667 | 2024 |
| Case Western Reserve University 34-1018992 | A | Cleveland, OH | 2 | $80,000 | 2024 |
| New York Weill Cornell Medical Center Fund Inc 13-6094042 | A | New York, NY | 2 | $80,000 | 2025 |
| Michigan State University 38-6005984 | A | East Lansing, MI | 2 | $80,000 | 2020 |
| Wake Forest University Health Sciences 22-3849199 | A | Winstonsalem, NC | 2 | $79,999 | 2021 |
| University of San Diego 94-3067788 | A | San Diego, CA | 2 | $50,000 | 2023 |
| Memorial Sloan Kettering Cancer Centre 13-1924236 | A | New York, NY | 2 | $50,000 | 2021 |
| Trustees of Boston University 04-2103547 | A | Boston, MA | 2 | $50,000 | 2024 |
| The General Hospital Corporation 04-2697983 | A | Boston, MA | 2 | $50,000 | 2025 |
| Huntsman Cancer Institute University of Utah 87-6000526 | A | Salt Lake City, UT | 1 | $43,333 | 2018 |
| National Cancer Institute 13-1837442 | A | New York, NY | 1 | $33,333 | 2025 |
| Indiana University School of Medicine 35-6001673 | A | Indianapolis, IN | 1 | $16,667 | 2018 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 26 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | National Cancer Institute New York, NY | A | $33,333 | paid | IMPROVING THE LIVES OF ALL PEOPLE THROUGH CANCER RESEARCH | 202641409349301144 |
| 2025 | New York Weill Cornell Medical Center Fund Inc New York, NY | A | $26,667 | paid | CHARACTERIZING THE ROLE AND TARGETING OF THE HISTONE METHYLTRANSFERASE SETD2 IN MULTIPLE MYELOMA. | 202641409349301144 |
| 2025 | The General Hospital Corporation Boston, MA | A | $16,667 | paid | ADVANCING SPINAL STABILITY IN MULTIPLE MYELOMA: A PREDICTIVE BIOMECHANICAL SIMULATION APPROACH. | 202641409349301144 |
| 2024 | New York Weill Cornell Medical Center Fund Inc New York, NY | A | $53,333 | paid | CHARACTERIZING THE ROLE AND TARGETING OF THE HISTONE METHYLTRANSFERASE SETD2 IN MULTIPLE MYELOMA. | 202511539349301151 |
| 2024 | The General Hospital Corporation Boston, MA | A | $33,333 | paid | ADVANCING SPINAL STABILITY IN MULTIPLE MYELOMA: A PREDICTIVE BIOMECHANICAL SIMULATION APPROACH. | 202511539349301151 |
| 2024 | Trustees of Boston University Boston, MA | A | $33,333 | paid | DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS. | 202511539349301151 |
| 2024 | Case Western Reserve University Cleveland, OH | A | $26,667 | paid | DECIPHERING THE EPIGENOMIC MECHANISMS OF TRANSFORMATION FROM BENIGN MONOCLONAL GAMMAPATHIES TO SYMPTOMATIC MULTIPLE MYELOMA. | 202511539349301151 |
| 2024 | Dana Farber Cancer Institute Boston, MA | A | $16,667 | paid | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | 202511539349301151 |
| 2023 | Case Western Reserve University Cleveland, OH | A | $53,333 | paid | NOVEL ADJUVANTS TO PROTEASOME INHIBITORS FOR MYELOMA THERAPY | 202442079349300024 |
| 2023 | Dana Farber Cancer Institute Boston, MA | A | $33,333 | paid | DEFINING CELL STATES UNDERLYING TREATMENT RESISTANCE IN MYELOMA BY INTEGRATING MULTIOMIC SEQUENCING DATA | 202442079349300024 |
| 2023 | Trustees of Boston University Boston, MA | A | $16,667 | paid | DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS | 202442079349300024 |
| 2023 | University of San Diego San Diego, CA | A | $16,667 | paid | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | 202442079349300024 |
| 2022 | University of San Diego San Diego, CA | A | $33,333 | paid | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | 202321529349300742 |
| 2022 | Dana Farber Cancer Institute Boston, MA | A | $16,667 | paid | CHARACTERIZATION OF RROL-DRIVEN LIPOGENIC SIGNALING IN MULTIPLE MYELOMA CELLS. | 202321529349300742 |
| 2021 | Dana Farber Cancer Institute Boston, MA | A | $33,333 | paid | CHARACTERIZATION OF RROL-DRIVEN LIPOGENIC SIGNALING IN MULTIPLE MYELOMA CELLS | 202202249349302825 |
| 2021 | Wake Forest University Health Sciences Winstonsalem, NC | A | $26,666 | paid | LEVERAGING POLYAMINE DEPENDENCY FOR TREATMENT OF DRUG RESISTANT MULTIPLE MYELOMAS | 202202249349302825 |
| 2021 | Memorial Sloan Kettering Cancer Centre New York, NY | A | $16,667 | paid | DECIPHERING THE IMPACT OF MELPHALAN ON SECONDARY MALIGNANCY IN MULTIPLE MYELOMA | 202202249349302825 |
| 2020 | Wake Forest University Health Sciences Winstonsalem, NC | A | $53,333 | paid | LEVERAGING POLYAMINE DEPENDENCY FOR TREATMENT OF DRUG RESISTANT MULTIPLE MYELOMAS | 202101559349300400 |
| 2020 | Memorial Sloan Kettering Cancer Centre New York, NY | A | $33,333 | paid | DECIPHERING THE IMPACT OF MELPHALAN ON SECONDARY MALIGNANCY IN MULTIPLE MYELOMA | 202101559349300400 |
| 2020 | Michigan State University East Lansing, MI | A | $26,667 | paid | TARGETING C-MYC DEGRADATION TO TREAT MULTIPLE MYELOMA | 202101559349300400 |
| 2020 | Dana Farber Cancer Institute Boston, MA | A | $16,667 | paid | OVERCOMING RESISTANCE TO PHARMACOLOGICAL DEGRADERS OF MYELOMA ONCOPROTEINS | 202101559349300400 |
| 2019 | Dana Farber Cancer Institute Boston, MA | A | $60,000 | paid | OVERCOMING RESISTANCE TO PHARMACOLOGICAL DEGRADERS OF MYELOMA ONCOPROTEINS AND RESEARCHING FUNCTIONAL ROLE OF CORE SPLICING FACTOR DEREGULATION IN MM PATHOGENESIS | 202011339349303416 |
| 2019 | Michigan State University East Lansing, MI | A | $53,333 | paid | TARGETING C-MYC DEGRADATION TO TREAT MULTIPLE MYELOMA | 202011339349303416 |
| 2018 | Dana Farber Cancer Institute Boston, MA | A | $70,000 | paid | TREATING MYELOMA THROUGH INDUCING DEGRADATION OF BET BROMODOMAIN PROTEINS, BLOOD BIOMARKERS FOR CLONAL PROGRESSION IN MULTIPLE MYELOMA AND INVESTIGATING THE ROLE OF ROBO1 IN MIGRATION AND HOMING IN MULTIPLE MYELOMA. | 201931339349307183 |
| 2018 | Huntsman Cancer Institute University of Utah Salt Lake City, UT | A | $43,333 | paid | GENERATION AND VALIDATION OF A MONOCLONAL ANTIBODY AGAINST VISTA FOR THE IMMUNOMODULATORY THERAPY OF MM AND ANTI-CD229 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATMENT OF MM. | 201931339349307183 |
| 2018 | Indiana University School of Medicine Indianapolis, IN | A | $16,667 | paid | BONE/BONE MARROW=TARGETED INHIBITION OF NOTCH SIGNALING IN COMBINATION WITH GLUCOCORTICOID THERAPY AS A NOVEL APPROACH TO TREAT MM. | 201931339349307183 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2025 | 2025-09-30 | not stated | 2024v5.5 | 202641409349301144 |
| 990 | 2024 | 2024-09-30 | not stated | 2023v6.0 | 202511539349301151 |
| 990 | 2023 | 2023-09-30 | not stated | 2022v5.0 | 202442079349300024 |
| 990 | 2022 | 2022-09-30 | not stated | 2021v4.2 | 202321529349300742 |
| 990 | 2021 | 2021-09-30 | not stated | 2020v4.2 | 202202249349302825 |
| 990 | 2020 | 2020-09-30 | not stated | 2019v5.2 | 202101559349300400 |
| 990 | 2019 | 2019-09-30 | not stated | 2018v3.1 | 202011339349303416 |
| 990 | 2018 | 2018-09-30 | not stated | 2017v2.3 | 201931339349307183 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/954296919.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.